Head-to-head · WeighScore
HealthSource vs REMEVi
The verdict
REMEVi takes it — 73.5/100 to 71.2/100.
REMEVi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | HealthSource | REMEVi |
|---|---|---|
| WeighScore | 71.2/100 | 73.5/100 |
| Grade | C | C |
| Scorecard rank | #96 | #70 |
| Semaglutide | $199/mo (all doses, compounded) | $219/mo |
| Tirzepatide | $299/mo (all doses, compounded) | $319/mo |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Yes |
Graded #96 · C
Strengths
- Three GLP-1 options: compounded semaglutide injection, tirzepatide injection, and oral sublingual tirzepatide
- 24/7 access to care team via HIPAA-compliant platform with unlimited physician messaging
- Every program covers the cost of medication, supplies, and telehealth visits — no separate pharmacy fee
- Subscription auto-refund if monthly reassessment is not completed
- Available in all 50 US states including Alaska and Hawaii with 3–5 day shipping
Where it loses points
- No physician names or clinical leadership disclosed on public pages
- No LegitScript certification found
- 503A partner pharmacy not named — less transparent than providers disclosing their 503B pharmacy
- Labs not mentioned on any product page — baseline bloodwork protocol unknown
- WooCommerce e-commerce storefront may feel more transactional than clinical
Graded #70 · C
Strengths
- A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
- Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
- A daily oral semaglutide tablet is offered alongside the injection
- Available in all 50 states and DC, with no minimum commitment and no cancellation fee
Where it loses points
- The flat rate is the highest entry price of the top-scoring programmes here; the cheaper $149 figure needs a full year
- No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.